Health Care [ 8/12 ] | Pharmaceuticals [ 48/74 ]
NASDAQ | Common Stock
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain.
Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia.
It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA; and Tulex Master, which develops, tests, and manufactures clinical supplies of SP-104.
Scilex Holding Company is based in Palo Alto, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 10, 26 | -1.17 Increased by +32.37% | -0.47 Decreased by -148.94% |
| Feb 25, 26 | -1.17 Increased by +50.57% | -0.47 Decreased by -149.28% |
| Nov 14, 25 | -21.29 Decreased by -1.46 K% | -0.41 Decreased by -5.09 K% |
| Aug 13, 25 | -7.42 Increased by +19.08% | -0.91 Decreased by -715.38% |
| May 14, 25 | -1.73 Increased by +76.46% | -0.01 Decreased by -17.20 K% |
| Mar 31, 25 | -2.37 Decreased by -848.00% | -3.15 Increased by +24.76% |
| Nov 27, 24 | -1.36 Increased by +93.81% | -3.50 Increased by +61.00% |
| Aug 13, 24 | -9.17 Decreased by -40.22% | -4.90 Decreased by -87.14% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 8.61 M Increased by +72.12% | -43.27 M Decreased by -65.91% | Decreased by -502.38% Increased by +3.61% |
| Dec 31, 25 | 4.79 M Decreased by -67.83% | -33.11 M Decreased by -412.57% | Decreased by -690.84% Decreased by -1.49 K% |
| Sep 30, 25 | 10.56 M Decreased by -26.85% | -257.23 M Decreased by -5.76 K% | Decreased by -2.44 K% Decreased by -7.91 K% |
| Jun 30, 25 | 9.90 M Decreased by -39.55% | -86.06 M Decreased by -129.00% | Decreased by -869.65% Decreased by -278.80% |
| Mar 31, 25 | 5.00 M Decreased by -54.02% | -26.08 M Decreased by -6.99% | Decreased by -521.18% Decreased by -132.70% |
| Dec 31, 24 | 14.90 M Increased by +10.68% | -6.46 M Increased by +69.81% | Decreased by -43.36% Increased by +72.73% |
| Sep 30, 24 | 14.44 M Increased by +42.69% | -4.39 M Increased by +87.65% | Decreased by -30.40% Increased by +91.34% |
| Jun 30, 24 | 16.37 M Increased by +30.11% | -37.58 M Decreased by -41.03% | Decreased by -229.58% Decreased by -8.39% |